Accurate prediction of target dose-escalation and organ-at-risk dose levels for non-small cell lung cancer patients

We have shown that the MLD and the prescribed PTV dose could be accurately predicted for NSCLC patients. This method can guide the treatment planner to achieve optimal OAR sparing and tumour dose escalation.